Healthcare · Biotechnology · NASDAQ
| Market cap | $1.28B |
|---|---|
| Trailing P/E | — |
| Price / book | 3.2 |
| Price / sales | — |
| FCF yield | -6.8% |
| Dividend yield | — |
| Gross margin | 0.0% |
| Operating margin | 0.0% |
| Net margin | 0.0% |
| Revenue growth (YoY) | — |
| Revenue growth (3-yr annual) | — |
| EPS growth (YoY) | — |
| FCF/share growth (YoY) | — |
| Beta | — |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
Next report: Mar 18, 2027 (Q4 2026, EPS estimate -$0.72). Beat the EPS estimate in 1 of 3 recent quarters.
| Quarter | Reported | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3 2026 | Nov 12, 2026 | -$0.67 | -$0.75 | +10.7% | $0 |
| Q2 2026 | Aug 12, 2026 | -$0.98 | -$0.56 | -75.0% | $0 |
| Q1 2026 | Jun 3, 2026 | -$21.83 | -$0.81 | -2595.1% | $0 |
Median target $60.00 from 5 analysts, ranging $52.00 – $80.00.
| Ticker | Company | Market cap | P/E |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $132.01B | 27.4 |
| REGN | Regeneron Pharmaceuticals | $95.52B | 16.7 |
| MRNA | Moderna | $80.65B | — |
| ARGX | argenx | $59.24B | 32.9 |
| ONC | BeOne Medicines | $45.66B | 50.8 |
| RPRX | Royalty Pharma | $38.94B | 12.8 |
| RVMD | Revolution Medicines | $34.48B | — |
| INSM | Insmed | $31.69B | — |